Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 85 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban February 7, 2022 Bus Driver Wears Different Costume Each Day To Make Kids Smile... January 27, 2022 African American Men More Likely to Die from Low-Grade Prostate Cancer January 28, 2019 FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease July 19, 2021 Load more HOT NEWS New study identifies how obesity may increase the risk of developing... Trial Establishes Preferred Treatment for Some People with Esophageal Cancer ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause...
